Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Period	Debt/Equity
2015-12-31	0.03
2016-12-31	0.16
2017-12-31	0.25
2018-12-31	2.93
2019-12-31	3.34
2020-12-31	2.28
2021-12-31	5.13
2022-12-31	-4.07
2023-12-31	5.74
2024-12-31	0.64

	A	B	C	D
1	Symbol	Price	Change	Volume
2	WVE	$7.28	+0.00%	4.07M
3
4
5

Wave Life Sciences Ltd. (WVE) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Wave Life Sciences Ltd. Data in Excel

More WVE Financial Data